| All Releases |
 |
October 18, 2010
Warner Chilcott Completes Acquisition of U.S. Rights to Enablex(R) Overactive Bladder Treatment for $400 Million in Cash |
 |
 |
| |
ARDEE, Ireland, Oct 18, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that it has completed its acquisition of the U.S. rights to Enablex(R) from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales... |
|
|
October 14, 2010
Warner Chilcott Announces Settlement with Lupin of Loestrin(R) 24 Fe and Femcon(R) Fe Patent Litigations |
|
|
| |
ARDEE, Ireland, Oct 14, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) and its subsidiary, Warner Chilcott Company, LLC, and Lupin Ltd. and its subsidiary, Lupin Pharmaceuticals, Inc., today announced that they have entered into a settlement agreement to resolve pending patent litigations involving Warner Chilcott's... |
|
|
October 11, 2010
Warner Chilcott Announces FDA Approval of Next Generation Actonel |
|
|
| |
ARDEE, Ireland, Oct 11, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL(R) (risedronate sodium) product for the treatment of postmenopausal osteoporosis in the United States. The product will be markete... |
|
|
September 29, 2010
Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering |
|
|
| |
ARDEE, Ireland, Sept 29, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced the closing of its offering of $500 million aggregate principal amount of 7 3/4% Senior Notes due 2018 (the "Notes") by its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (each a co-issuer, and togethe... |
|
|
September 24, 2010
Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex(R) |
|
|
| |
ARDEE, Ireland, Sept 24, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (each a co-issuer, and together, the "Issuers"), sold $500 million aggregate principal amount of 7-3/4% Senior Notes due 2018 (the "Notes") in a ... |
|
|
September 24, 2010
Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex(R) |
|
|
| |
ARDEE, Ireland, Sept 24, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (together, the "Issuers"), plan to issue an aggregate principal amount of $500 million of 7-3/4% senior notes due 2018 (the "Notes") in a private... |
|
|
September 24, 2010
Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex(R) Overactive Bladder Treatment for $400 Million in Cash |
|
|
| |
ARDEE, Ireland, Sept 24, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex(R) from Novartis for $400 million in cash. Enablex (darifenacin) is a pro... |
|
|
September 16, 2010
Warner Chilcott to Present at UBS Global Life Sciences Conference |
|
|
| |
ARDEE, Ireland, Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that its Executive Vice President and Chief Financial Officer Paul Herendeen is scheduled to speak at the UBS Global Life Sciences Conference in New York on Tuesday, September 21st at 12:30 p.m. ET. The presentation will be simu... |
|
|
August 24, 2010
Warner Chilcott Announces Receipt of FDA Response to Citizen Petition |
|
|
| |
ARDEE, Ireland, Aug 24, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that it has received the Food and Drug Administration's ("FDA's") response to a citizen petition it had filed regarding its ASACOL and ASACOL HD products. In its petition, Warner Chilcott requested that the FDA (1) issue bioequiv... |
|
| |
August 24, 2010
FDA Response Letter |
|
|
|
August 20, 2010
Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance |
|
|
| |
ARDEE, Ireland, Aug 20, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that it has completed an amendment to its existing senior secured credit facilities, pursuant to which it has incurred an additional $1.5 billion aggregate principal amount of new term loans. The new term loan facilities are comp... |
|
|
August 12, 2010
Warner Chilcott Announces Pricing of $750 Million of Senior Notes in Connection with Proposed Leveraged Recapitalization |
|
|
| |
ARDEE, Ireland, Aug 12, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (each a co-issuer, and together, the "Issuers"), sold $750 million aggregate principal amount of 7-3/4% Senior Notes due 2018 (the "Notes") in a p... |
|
|
August 12, 2010
Warner Chilcott Announces $750 Million Senior Notes Offering in Connection with Proposed Leveraged Recapitalization |
|
|
| |
ARDEE, Ireland, Aug 12, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (each a co-issuer, and together, the "Issuers"), plan to issue an aggregate principal amount of $750 million of senior notes due 2018 (the "Notes"... |
|
|
August 6, 2010
Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2010 |
|
|
| |
ARDEE, Ireland, Aug 06, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced its results for the quarter ended June 30, 2010. Revenue in the quarter ending June 30, 2010 increased 225.2% to $815.6 million over the prior year quarter. The primary drivers of the increase in revenue were the products acquired... |
|
|
July 30, 2010
Warner Chilcott Announces Proposed Leveraged Recapitalization Including Special Cash Dividend to Shareholders and Updates Full-Year 2010 Financial Guidance |
|
|
| |
ARDEE, Ireland, July 30, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced a recapitalization pursuant to which it intends to incur, subject to market and other conditions, $2.25 billion of new debt to fund a special dividend to Warner Chilcott's ordinary shareholders of $8.50 per share, or approximatel... |
|
|
July 30, 2010
Information regarding the tax treatment of the proposed special cash dividend |
|
|
| |
On July 30, 2010, the Company announced a recapitalization pursuant to which it intends to incur, subject to market and other conditions, $2.25 billion of new debt to fund a special cash dividend to its ordinary shareholders of $8.50 per share, or approximately $2.15 billion in the aggregate. The new debt is expected to be comprised of a combinati... |
|
|
July 28, 2010
Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results |
|
|
| |
ARDEE, Ireland, July 28, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that it will issue its second quarter 2010 financial results prior to the market opening on Friday, August 6, 2010.
In addition to issuing a press release, the Company will host a conference call for all interested parties on Fr... |
|
|
July 16, 2010
Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product |
|
|
| |
ARDEE, Ireland, July 16, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that it has received a communication from the U.S. Food & Drug Administration (FDA) related to its next generation Actonel(R) product (risedronate sodium) delayed-release tablets extending the Prescription Drug User Fee Act (PDUF... |
|
|
June 28, 2010
Warner Chilcott Announces Receipt of Paragraph IV Certification Notice |
|
|
| |
ARDEE, Ireland, June 28, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that it has received a Paragraph IV Certification Notice from Par Pharmaceutical, Inc. ("Par"). The Paragraph IV Certification Notice advises the Company of the filing of an Abbreviated New Drug Application (ANDA) by Par for a g... |
|
|
June 21, 2010
Warner Chilcott to Present at the Wells Fargo Securities Healthcare Conference |
|
|
| |
ARDEE, Ireland, June 21, 2010 /PRNewswire via COMTEX News Network/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that it will present at the Wells Fargo Securities Healthcare Conference on Wednesday, June 23, 2010 at 3:00 p.m. EDT. Presenting for Warner Chilcott will be Paul Herendeen, Executive Vice President and Chief Financial Officer.
... |
|
|
|
Investor Relations
